Rybelsus 3mg Tablet is an oral formulation developed by Novo Nordisk containing semaglutide, an incretin-like mediator called GLP-1 receptor agonist.
Injectable semaglutide and Rybelsus are different products. The latter is in the form of a pill to be administered once daily.
By stimulating GLP-1 cell receptors controlling appetite and insulin secretion, semaglutide causes a decrease in hunger, increase in the feeling of satisfaction, and less food eaten in one sitting. The outcome is that weight loss takes place. It is under the trade name Wegovy that Australian regulatory authorities have approved semaglutide, the first product in this class, for long-term weight management.
Rybelsus tablet 3mg dosage is the minimum strength used usually during the first month only if no progression to a stronger tablet, ie 7mg of product is needed.
How Does Rybelsus 3mg Work?
Rybelsus contains semaglutide, which mimics the action of GLP-1, a naturally occurring hormone involved in appetite and glucose regulation.
Semaglutide can:
- increase feelings of fullness
- reduce hunger
- reduce food intake
- slow gastric emptying
- help regulate blood glucose
- reduce food cravings
These effects may contribute to weight loss in some people. However, Rybelsus should be used according to its approved indication and under medical supervision.
Rybelsus 3mg Composition
Active ingredient
Each tablet containsSemaglutide 3 mg
The Australian Rybelsus range contains 3 mg and 7 mg tablets. The 3 mg product is listed on the Australian Register of Therapeutic Goods under ARTG 346198.
Rybelsus is a medicine that you take by mouth; therefore, it does not involve a pen or needle for injections.
How to Take Rybelsus 3mg
Rybelsus has specific ways of how it should be taken because the timing of intake influences the amount of semaglutide absorbed by the body.
Take the Rybelsus tablet:
- One time every day, in the morning, when you still have an empty stomach, i.e., before eating or drinking anything except water.
- Swallow whole with water (up to 120 mL of regular water).
- Do not crush, break, or chew the tablet.
- Keep a food, drink, or medication intake gap of at least 30 minutes after taking the Rybelsus tablet.
Compliant use of the medication is of utmost importance with oral semaglutide. Delayed food, drinks, or medicines may hinder drug absorption by the body.
Rybelsus 3mg Dosage
Rybelsus 3mg is the starting dose.
The Australian product information recommends:
| Treatment period | Daily dose |
| First month | 3mg once daily |
| After at least 1 month | 7mg once daily |
| If additional glucose control is needed | 14mg once daily |
The 3mg dose is intended primarily to help the body adjust to treatment and is not considered a maintenance dose.
The dose should only be increased according to your doctor’s instructions.
Missed Dose
In the case that you forget to take Rybelsus, the Australian product information suggests that you may skip the missed dose and take only a single tablet the following day.
It’s important to note that two tablets should not be swallowed together as compensation for forgetting to take an earlier dose.
Can Rybelsus 3mg Help With Weight Loss?
It can contribute to weight reduction because semaglutide affects appetite and energy intake.
The 3mg strength is also a starting dose, rather than the dose used for longer-term treatment. Therefore, people should not expect the same effect from 3mg as from higher maintenance doses used in other semaglutide treatment regimens.
If treatment is being considered specifically for chronic weight management, a doctor can assess whether an appropriately indicated medicine such as Wegovy is suitable.
Possible Side Effects
Digestive side effects are among the most commonly reported effects of semaglutide.
These may include:
- nausea
- diarrhoea
- vomiting
- constipation
- abdominal pain
- reduced appetite
- indigestion
- bloating
- reflux or belching
- headache
- dizziness
- tiredness
Gastrointestinal symptoms can be particularly noticeable when treatment is first started or when the dose is increased.
Dehydration
Vomiting and diarrhoea can result in dehydration. In some cases, significant fluid loss can contribute to worsening kidney function. The Australian product information recommends taking precautions to avoid dehydration if gastrointestinal side effects occur.
Pancreatitis
Acute pancreatitis has been observed with GLP-1 receptor agonists. If you develop severe or persistent abdominal pain, particularly with nausea or vomiting, seek medical attention. If pancreatitis is confirmed, Rybelsus should not be restarted.
Precautions
Tell your doctor if you have:
- a history of pancreatitis
- kidney problems
- liver problems
- significant gastrointestinal disease
- diabetic retinopathy
- type 1 diabetes
- a planned operation or procedure involving anaesthesia
- an allergy to semaglutide or any ingredient in the tablet
The Australian product information notes that safety and effectiveness in people under 18 have not been established.
People with a history of diabetic retinopathy should also be monitored because rapid improvement in blood-glucose control can temporarily worsen diabetic retinopathy.
Rybelsus 3mg and Other Medicines
Semaglutide delays gastric emptying and can therefore influence the absorption of some oral medicines.
Particular attention may be needed with:
- levothyroxine
- warfarin and other coumarin medicines
- insulin
- sulfonylureas
- medicines requiring careful monitoring
The Australian product information notes that levothyroxine exposure increased when given with semaglutide and recommends consideration of thyroid-parameter monitoring. For patients taking warfarin or other coumarin derivatives, more frequent INR monitoring is recommended when semaglutide is started.
Tell your doctor or pharmacist about all medicines, vitamins and supplements you take.
Rybelsus 3mg and Pregnancy
Rybelsus should not be used for weight loss during pregnancy.
If you are pregnant, planning pregnancy or breastfeeding, discuss semaglutide treatment with your doctor before taking Rybelsus. Healthdirect recommends seeking professional advice about semaglutide during pregnancy.
How to Store Rybelsus 3mg
According to current Healthdirect information, Rybelsus 3mg tablets should be stored below 30°C.
The TGA assessment also describes storage below 30°C with protection from light and moisture.
Keep the tablets:
- below 30°C
- protected from moisture
- protected from direct light
- in their original packaging
- out of reach of children
Rybelsus does not require refrigeration like injectable semaglutide products.
Rybelsus 3mg vs Wegovy for Weight Loss
Both contain semaglutide, but their approved uses and administration are different.
| Feature | Rybelsus 3mg | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Form | Tablet | Injection |
| Frequency | Once daily | Once weekly |
| 3mg role | Starting dose | Not applicable |
FAQs
1. Is Rybelsus 3mg only used for the first month?
Under the Australian dosing schedule, 3mg is the starting dose used for one month before increasing to 7mg. It is intended to help the body adjust to treatment rather than provide the full maintenance effect.
2. Can Rybelsus 3mg cause reduced appetite?
Yes. Semaglutide can reduce appetite and increase feelings of fullness. The TGA notes that reduced appetite, increased satiety and decreased food cravings contribute to lower energy intake and weight reduction.
3. Does Rybelsus 3mg affect the absorption of other tablets?
It can. Semaglutide delays gastric emptying, which may influence the absorption of some oral medicines. This is particularly relevant for medicines such as levothyroxine, where monitoring may be appropriate.
4. Can Rybelsus 3mg be used by someone with kidney problems?
The Australian product information states that no dose adjustment is required for mild, moderate or severe renal impairment, but experience in severe renal impairment is limited and semaglutide is not recommended in end-stage renal disease. Dehydration from vomiting or diarrhoea can also affect kidney function.
Medical Disclaimer
Rybelsus 3mg is a prescription medicine containing semaglutide. It can reduce appetite and body weight. Do not start Rybelsus, increase the dose or use it together with another semaglutide medicine without medical advice.
References
- TGA Australia — Rybelsus: (Therapeutic Goods Administration (TGA))
- TGA Australia — Rybelsus 3mg ARTG 346198: (Therapeutic Goods Administration (TGA))
- TGA Australia — Rybelsus Product Information: (Therapeutic Goods Administration (TGA))
- Healthdirect Australia — Rybelsus: (Healthdirect)
